1-4 of 4
Oliver Schadt
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations

Joachim Albers, Manja Friese-Hamim, Anderson Clark, Oliver Schadt, Gina Walter-Bausch, Christopher Stroh, Andreas Johne, Niki Karachaliou, Andree Blaukat
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (7): 833–843.
https://doi.org/10.1158/1535-7163.MCT-22-0537
Published: 05 July 2023
View article titled, The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring <em>MET</em> Alterations
Open the PDF for The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring <em>MET</em> Alterations in another window
Journal Articles

M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models

Michael P. Sanderson, Manja Friese-Hamim, Gina Walter-Bausch, Michael Busch, Stefanie Gaus, Djordje Musil, Felix Rohdich, Ugo Zanelli, Sondra L. Downey-Kopyscinski, Constantine S. Mitsiades, Oliver Schadt, Markus Klein, Christina Esdar
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (8): 1378–1387.
https://doi.org/10.1158/1535-7163.MCT-21-0005
Published: 01 August 2021
View article titled, M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models
Open the PDF for M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models in another window
Includes: Supplementary data
Journal Articles

Abstract B252: Identification of a new class of highly potent and selective c‐Met kinase inhibitors

Andree Blaukat, Friedhelm Bladt, Dieter Dorsch, Claus Fittschen, Manja Friese‐Hamim, Ulrich Graedler, Michael Meyring, Wilfried Rautenberg, Oliver Schadt, Frank Stieber
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B252.
https://doi.org/10.1158/1535-7163.TARG-09-B252
Published: 10 December 2009
View article titled, Abstract B252: Identification of a new class of highly potent and selective c‐Met kinase inhibitors
Journal Articles

Novel 1-acyl-pyrazoline derivatives as highly selective inhibitors of c-Met-kinase

Dieter Dorsch, Oliver Schadt, Melanie Schultz, Andree Blaukat, Wilfried Rautenberg, Ulrich Graedler, Michael Meyring
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A241.
Published: 01 November 2007
View article titled, Novel 1-acyl-pyrazoline derivatives as highly selective inhibitors of c-Met-kinase